Reports Q3 revenue $278.000, consensus $330,000. "We reported revenue in the third quarter of $278,000, which represents an approximately 50% increase compared with the second quarter of 2022, and our highest quarterly revenue to date. We continue to drive steady quarterly growth since our launch of Pure-Vu EVS six months ago. We believe our results are driven by an expanded commercial footprint and the positive attributes of the Pure-Vu EVS system," commented Tim Moran, CEO. "There are approximately 25 hospitals with our system in place, which includes a balanced mix of academic, community, and VA hospitals. While the third quarter represented a solid performance, we did see a few accounts push their purchasing decision to the fourth quarter, which we believe is mainly due to capital budget constraints and continued hospital staffing challenges."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MOTS:
- Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update
- Motus GI to Release Third Quarter Results and Provide a Business Update on November 14
- Motus GI Announces Positive Clinical Data for Pure-Vu EVS in Three Poster Presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
- Motus GI Granted a U.S. Patent for Prepless Colonoscopy Methods Embodied by the Pure-Vu® System
- Motus GI Named a Sole Source Supplier with U.S. Department of Veteran Affairs